Good God! Is anyone actually supporting this ARNA fantasy in the investor community? What a load of cr@p. Now, if the drug had potentially better efficacy, maybe, somehow, someway, you could hold out hope after a few more years of effort and work on the drug. But if I recall correctly this drug's efficacy was on the smallish side, at least compared to that demonstrated by its phase III compatriots including VVUS, and in comparison to the phase II drug by AMLN.
Exactly why would the FDA want to approve a minimially effective drug that has potentail fen-phen like liability issues? Why would ARNA want to, except for the fact they have no other choice?
Anyone here ever see the FDA accept pooled clinical data to prove something that one clinical trial itself could not prove?
Maybe, but I've never seen it.
Tinker
